Comparison
Hexarelin vs. Liraglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
140703-51-1
204656-20-2
Molecular weight
887.05 g/mol
3751 g/mol
Half-life
0.9 h
13 h
Sequence
His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGMechanism of action
Hexarelin
Hexarelin is a synthetic analog of the GHRP-6 family binding both the GH secretagogue receptor (GHSR-1a) and CD36. GHSR activation in the pituitary releases pulsatile growth hormone. Via CD36 in endothelium and myocardium, cardioprotective effects have been described in animal studies.
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
5
of which in humans
3
4
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
1